The Use of Liraglutide in Brain Death

NCT03672812 on ClinicalTrials.gov · last registry update 2024-03-05

A small phase 3 — 50 participants, against a typical 424. The sponsor logged completion for 10 December 2019. Primary outcome, as filed: change inflammation.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hospital de Clinicas de Porto Alegre
Sponsor type: Other
Enrollment: 50
Started: 2018-09-01
Primary completion: 2019-12-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

change inflammation

Conditions studied

Brain Death

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.